

# Andrey G Korshunov

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4912593/publications.pdf>

Version: 2024-02-01

259  
papers

46,649  
citations

1893  
102  
h-index

1980  
206  
g-index

273  
all docs

273  
docs citations

273  
times ranked

33593  
citing authors

#	ARTICLE	IF	CITATIONS
1	Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. <i>Nature</i> , 2012, 482, 226-231.	27.8	2,129
2	Pan-cancer analysis of whole genomes. <i>Nature</i> , 2020, 578, 82-93.	27.8	1,966
3	DNA methylation-based classification of central nervous system tumours. <i>Nature</i> , 2018, 555, 469-474.	27.8	1,872
4	Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma. <i>Cancer Cell</i> , 2012, 22, 425-437.	16.8	1,551
5	Molecular subgroups of medulloblastoma: the current consensus. <i>Acta Neuropathologica</i> , 2012, 123, 465-472.	7.7	1,536
6	Medulloblastoma Comprises Four Distinct Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 1408-1414.	1.6	1,131
7	Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. <i>Cancer Cell</i> , 2015, 27, 728-743.	16.8	933
8	Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 397-405.	7.7	914
9	Analysis of the IDH1 codon 132 mutation in brain tumors. <i>Acta Neuropathologica</i> , 2008, 116, 597-602.	7.7	910
10	Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. <i>Acta Neuropathologica</i> , 2012, 123, 473-484.	7.7	863
11	K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. <i>Acta Neuropathologica</i> , 2012, 124, 439-447.	7.7	799
12	The whole-genome landscape of medulloblastoma subtypes. <i>Nature</i> , 2017, 547, 311-317.	27.8	787
13	Dissecting the genomic complexity underlying medulloblastoma. <i>Nature</i> , 2012, 488, 100-105.	27.8	765
14	Subgroup-specific structural variation across 1,000 medulloblastoma genomes. <i>Nature</i> , 2012, 488, 49-56.	27.8	761
15	Genome Sequencing of Pediatric Medulloblastoma Links Catastrophic DNA Rearrangements with TP53 Mutations. <i>Cell</i> , 2012, 148, 59-71.	28.9	743
16	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. <i>Cell</i> , 2016, 164, 1060-1072.	28.9	702
17	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	21.4	674
18	Reduced H3K27me3 and DNA Hypomethylation Are Major Drivers of Gene Expression in K27M Mutant Pediatric High-Grade Gliomas. <i>Cancer Cell</i> , 2013, 24, 660-672.	16.8	633

#	ARTICLE	IF	CITATIONS
19	Genome Sequencing of SHH Medulloblastoma Predicts Genotype-Related Response to Smoothed Inhibition. <i>Cancer Cell</i> , 2014, 25, 393-405.	16.8	627
20	Medulloblastomics: the end of the beginning. <i>Nature Reviews Cancer</i> , 2012, 12, 818-834.	28.4	560
21	Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014, 506, 445-450.	27.8	521
22	Enhancer hijacking activates GF11 family oncogenes in medulloblastoma. <i>Nature</i> , 2014, 511, 428-434.	27.8	520
23	International Society of Neuro-pathology & Neuro-oncology consensus guidelines for neurovascular system tumor classification and grading. <i>Brain Pathology</i> , 2014, 24, 429-435.	4.1	499
24	Delineation of Two Clinically and Molecularly Distinct Subgroups of Posterior Fossa Ependymoma. <i>Cancer Cell</i> , 2011, 20, 143-157.	16.8	494
25	Characterization of R132H Mutation-specific IDH1 Antibody Binding in Brain Tumors. <i>Brain Pathology</i> , 2010, 20, 245-254.	4.1	463
26	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. <i>Cancer Cell</i> , 2016, 29, 379-393.	16.8	438
27	BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas. <i>Journal of Clinical Investigation</i> , 2008, 118, 1739-1749.	8.2	437
28	Subgroup-Specific Prognostic Implications of TP53 Mutation in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2927-2935.	1.6	381
29	Decoding the regulatory landscape of medulloblastoma using DNA methylation sequencing. <i>Nature</i> , 2014, 510, 537-541.	27.8	378
30	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an integrated diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. <i>Acta Neuropathologica</i> , 2015, 129, 133-146.	7.7	378
31	Frequent ATRX mutations and loss of expression in adult diffuse astrocytic tumors carrying IDH1/IDH2 and TP53 mutations. <i>Acta Neuropathologica</i> , 2012, 124, 615-625.	7.7	376
32	Clonal selection drives genetic divergence of metastatic medulloblastoma. <i>Nature</i> , 2012, 482, 529-533.	27.8	376
33	The eEF2 Kinase Confers Resistance to Nutrient Deprivation by Blocking Translation Elongation. <i>Cell</i> , 2013, 153, 1064-1079.	28.9	348
34	Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. <i>Acta Neuropathologica</i> , 2012, 123, 615-626.	7.7	318
35	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	27.8	318
36	Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience. <i>Acta Neuropathologica</i> , 2018, 136, 181-210.	7.7	308

#	ARTICLE	IF	CITATIONS
37	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2013, 14, 1200-1207.	10.7	307
38	ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. <i>Acta Neuropathologica</i> , 2013, 126, 443-451.	7.7	304
39	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. <i>Acta Neuropathologica</i> , 2018, 136, 153-166.	7.7	298
40	Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. <i>Acta Neuropathologica</i> , 2015, 129, 669-678.	7.7	277
41	Outcome Prediction in Pediatric Medulloblastoma Based on DNA Copy-Number Aberrations of Chromosomes 6q and 17q and the <i>MYC</i> and <i>MYCN</i> Loci. <i>Journal of Clinical Oncology</i> , 2009, 27, 1627-1636.	1.6	274
42	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. <i>Lancet Oncology</i> , The, 2016, 17, 484-495.	10.7	274
43	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. <i>Acta Neuropathologica</i> , 2015, 129, 867-873.	7.7	272
44	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	7.7	271
45	Spectrum and prevalence of genetic predisposition in medulloblastoma: a retrospective genetic study and prospective validation in a clinical trial cohort. <i>Lancet Oncology</i> , The, 2018, 19, 785-798.	10.7	268
46	An Animal Model of MYC-Driven Medulloblastoma. <i>Cancer Cell</i> , 2012, 21, 155-167.	16.8	267
47	A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing. <i>Nature Communications</i> , 2015, 6, 10001.	12.8	266
48	Divergent clonal selection dominates medulloblastoma at recurrence. <i>Nature</i> , 2016, 529, 351-357.	27.8	266
49	Cytogenetic Prognostication Within Medulloblastoma Subgroups. <i>Journal of Clinical Oncology</i> , 2014, 32, 886-896.	1.6	263
50	The clinical implications of medulloblastoma subgroups. <i>Nature Reviews Neurology</i> , 2012, 8, 340-351.	10.1	261
51	Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. <i>Acta Neuropathologica</i> , 2009, 118, 401-405.	7.7	255
52	Distribution of TERT promoter mutations in pediatric and adult tumors of the nervous system. <i>Acta Neuropathologica</i> , 2013, 126, 907-915.	7.7	254
53	Mutations in SETD2 and genes affecting histone H3K36 methylation target hemispheric high-grade gliomas. <i>Acta Neuropathologica</i> , 2013, 125, 659-669.	7.7	250
54	Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. <i>Acta Neuropathologica</i> , 2013, 125, 913-916.	7.7	244

#	ARTICLE	IF	CITATIONS
55	Somatic CRISPR/Cas9-mediated tumour suppressor disruption enables versatile brain tumour modelling. <i>Nature Communications</i> , 2015, 6, 7391.	12.8	244
56	Quiescent Sox2+ Cells Drive Hierarchical Growth and Relapse in Sonic Hedgehog Subgroup Medulloblastoma. <i>Cancer Cell</i> , 2014, 26, 33-47.	16.8	241
57	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. <i>Acta Neuropathologica</i> , 2015, 130, 407-417.	7.7	237
58	Sarcoma classification by DNA methylation profiling. <i>Nature Communications</i> , 2021, 12, 498.	12.8	237
59	BAF complexes facilitate decatenation of DNA by topoisomerase II±. <i>Nature</i> , 2013, 497, 624-627.	27.8	230
60	Adult Medulloblastoma Comprises Three Major Molecular Variants. <i>Journal of Clinical Oncology</i> , 2011, 29, 2717-2723.	1.6	215
61	Identification of Gains on 1q and Epidermal Growth Factor Receptor Overexpression as Independent Prognostic Markers in Intracranial Ependymoma. <i>Clinical Cancer Research</i> , 2006, 12, 2070-2079.	7.0	212
62	Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2011, 121, 763-774.	7.7	211
63	Molecular Staging of Intracranial Ependymoma in Children and Adults. <i>Journal of Clinical Oncology</i> , 2010, 28, 3182-3190.	1.6	210
64	Genomic and Protein Expression Profiling Identifies CDK6 As Novel Independent Prognostic Marker in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2005, 23, 8853-8862.	1.6	207
65	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. <i>Acta Neuropathologica</i> , 2016, 131, 903-910.	7.7	203
66	Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas. <i>Acta Neuropathologica</i> , 2018, 136, 211-226.	7.7	199
67	Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinct. <i>Acta Neuropathologica</i> , 2011, 122, 231-240.	7.7	195
68	Embryonal tumor with abundant neuropil and true rosettes (ETANTR), ependymoblastoma, and medulloepithelioma share molecular similarity and comprise a single clinicopathological entity. <i>Acta Neuropathologica</i> , 2014, 128, 279-289.	7.7	191
69	Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations. <i>Acta Neuropathologica</i> , 2018, 136, 273-291.	7.7	190
70	Recurrent MET fusion genes represent a drug target in pediatric glioblastoma. <i>Nature Medicine</i> , 2016, 22, 1314-1320.	30.7	183
71	Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes. <i>Acta Neuropathologica</i> , 2019, 138, 309-326.	7.7	180
72	Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma. <i>Acta Neuropathologica</i> , 2014, 128, 561-571.	7.7	176

#	ARTICLE	IF	CITATIONS
73	HDAC5 and HDAC9 in Medulloblastoma: Novel Markers for Risk Stratification and Role in Tumor Cell Growth. <i>Clinical Cancer Research</i> , 2010, 16, 3240-3252.	7.0	175
74	Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas. <i>Neuro-Oncology</i> , 2014, 16, 1408-1416.	1.2	175
75	Therapeutic targeting of ependymoma as informed by oncogenic enhancer profiling. <i>Nature</i> , 2018, 553, 101-105.	27.8	170
76	Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 125, 373-384.	7.7	169
77	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. <i>Acta Neuropathologica</i> , 2017, 134, 705-714.	7.7	168
78	Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity. <i>Acta Neuropathologica</i> , 2016, 131, 137-146.	7.7	162
79	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. <i>Journal of Clinical Oncology</i> , 2016, 34, 2468-2477.	1.6	160
80	Infant High-Grade Gliomas Comprise Multiple Subgroups Characterized by Novel Targetable Gene Fusions and Favorable Outcomes. <i>Cancer Discovery</i> , 2020, 10, 942-963.	9.4	157
81	Risk-adapted therapy for young children with medulloblastoma (SJYC07): therapeutic and molecular outcomes from a multicentre, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 768-784.	10.7	151
82	The Next Generation of Glioma Biomarkers: MGMT Methylation, BRAF Fusions and IDH1 Mutations. <i>Brain Pathology</i> , 2011, 21, 74-87.	4.1	150
83	Gene Expression Patterns in Ependymomas Correlate with Tumor Location, Grade, and Patient Age. <i>American Journal of Pathology</i> , 2003, 163, 1721-1727.	3.8	149
84	Markers of survival and metastatic potential in childhood CNS primitive neuro-ectodermal brain tumours: an integrative genomic analysis. <i>Lancet Oncology</i> , The, 2012, 13, 838-848.	10.7	148
85	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. <i>Acta Neuropathologica</i> , 2013, 126, 917-929.	7.7	146
86	Proteomics, Post-translational Modifications, and Integrative Analyses Reveal Molecular Heterogeneity within Medulloblastoma Subgroups. <i>Cancer Cell</i> , 2018, 34, 396-410.e8.	16.8	146
87	H3-/IDH-wild type pediatric glioblastoma is comprised of molecularly and prognostically distinct subtypes with associated oncogenic drivers. <i>Acta Neuropathologica</i> , 2017, 134, 507-516.	7.7	144
88	<i>FSTL5</i> Is a Marker of Poor Prognosis in Non-WNT/Non-SHH Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2011, 29, 3852-3861.	1.6	143
89	Microarray-Based Screening for Molecular Markers in Medulloblastoma Revealed STK15 as Independent Predictor for Survival. <i>Cancer Research</i> , 2004, 64, 3103-3111.	0.9	139
90	Adult and Pediatric Medulloblastomas Are Genetically Distinct and Require Different Algorithms for Molecular Risk Stratification. <i>Journal of Clinical Oncology</i> , 2010, 28, 3054-3060.	1.6	136

#	ARTICLE	IF	CITATIONS
91	Genetic Aberrations Leading to MAPK Pathway Activation Mediate Oncogene-Induced Senescence in Sporadic Pilocytic Astrocytomas. <i>Clinical Cancer Research</i> , 2011, 17, 4650-4660.	7.0	135
92	Focal genomic amplification at 19q13.42 comprises a powerful diagnostic marker for embryonal tumors with ependymoblastic rosettes. <i>Acta Neuropathologica</i> , 2010, 120, 253-260.	7.7	129
93	Poorly differentiated chordoma with SMARCB1/INI1 loss: a distinct molecular entity with dismal prognosis. <i>Acta Neuropathologica</i> , 2016, 132, 149-151.	7.7	127
94	Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort. <i>Acta Neuropathologica</i> , 2014, 128, 137-149.	7.7	125
95	The histologic grade is a main prognostic factor for patients with intracranial ependymomas treated in the microneurosurgical era. <i>Cancer</i> , 2004, 100, 1230-1237.	4.1	124
96	A biobank of patient-derived pediatric brain tumor models. <i>Nature Medicine</i> , 2018, 24, 1752-1761.	30.7	124
97	Targeting Self-Renewal in High-Grade Brain Tumors Leads to Loss of Brain Tumor Stem Cells and Prolonged Survival. <i>Cell Stem Cell</i> , 2014, 15, 185-198.	11.1	123
98	Chd7 is indispensable for mammalian brain development through activation of a neuronal differentiation programme. <i>Nature Communications</i> , 2017, 8, 14758.	12.8	118
99	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. <i>Acta Neuropathologica</i> , 2018, 136, 239-253.	7.7	118
100	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2014, 128, 733-741.	7.7	116
101	LIN28A immunoreactivity is a potent diagnostic marker of embryonal tumor with multilayered rosettes (ETMR). <i>Acta Neuropathologica</i> , 2012, 124, 875-881.	7.7	115
102	Acyl-CoA-Binding Protein Drives Glioblastoma Tumorigenesis by Sustaining Fatty Acid Oxidation. <i>Cell Metabolism</i> , 2019, 30, 274-289.e5.	16.2	115
103	Spatial heterogeneity in medulloblastoma. <i>Nature Genetics</i> , 2017, 49, 780-788.	21.4	112
104	HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. <i>Journal of Neuro-Oncology</i> , 2012, 110, 335-348.	2.9	110
105	Novel genomic amplification targeting the microRNA cluster at 19q13.42 in a pediatric embryonal tumor with abundant neuropil and true rosettes. <i>Acta Neuropathologica</i> , 2009, 117, 457-464.	7.7	106
106	Aberrant ERBB4-SRC Signaling as a Hallmark of Group 4 Medulloblastoma Revealed by Integrative Phosphoproteomic Profiling. <i>Cancer Cell</i> , 2018, 34, 379-395.e7.	16.8	104
107	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. <i>Acta Neuropathologica</i> , 2018, 136, 327-337.	7.7	104
108	MYCN amplification drives an aggressive form of spinal ependymoma. <i>Acta Neuropathologica</i> , 2019, 138, 1075-1089.	7.7	104

#	ARTICLE	IF	CITATIONS
109	<i>TP53</i> Mutation Is Frequently Associated With <i>CTNNB1</i> Mutation or <i>MYCN</i> Amplification and Is Compatible With Long-Term Survival in Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 5188-5196.	1.6	100
110	Epithelioid Glioblastomas and Anaplastic Epithelioid Pleomorphic Xanthoastrocytomasâ€”Same Entity or First Cousins?. <i>Brain Pathology</i> , 2016, 26, 215-223.	4.1	95
111	The molecular landscape of ETMR at diagnosis and relapse. <i>Nature</i> , 2019, 576, 274-280.	27.8	94
112	Germline Elongator mutations in Sonic Hedgehog medulloblastoma. <i>Nature</i> , 2020, 580, 396-401.	27.8	94
113	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	28.9	93
114	Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis. <i>Brain Pathology</i> , 2018, 28, 656-662.	4.1	89
115	MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 501-513.	7.7	87
116	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	7.7	86
117	Differential expression and methylation of brain developmental genes define location-specific subsets of pilocytic astrocytoma. <i>Acta Neuropathologica</i> , 2013, 126, 291-301.	7.7	84
118	Molecular diagnostics of CNS embryonal tumors. <i>Acta Neuropathologica</i> , 2010, 120, 553-566.	7.7	83
119	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	7.7	83
120	Medulloblastoma subgroups remain stable across primary and metastatic compartments. <i>Acta Neuropathologica</i> , 2015, 129, 449-457.	7.7	80
121	A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat. <i>Acta Neuropathologica</i> , 2011, 122, 637-650.	7.7	77
122	Supratentorial primitive neuroectodermal tumors of the central nervous system frequently harbor deletions of the CDKN2A locus and other genomic aberrations distinct from medulloblastomas. <i>Genes Chromosomes and Cancer</i> , 2007, 46, 839-851.	2.8	76
123	Functional characterization of a <i>BRAF</i> insertion mutant associated with pilocytic astrocytoma. <i>International Journal of Cancer</i> , 2011, 129, 2297-2303.	5.1	75
124	A subset of pediatric-type thalamic gliomas share a distinct DNA methylation profile, H3K27me3 loss and frequent alteration of <i>EGFR</i> . <i>Neuro-Oncology</i> , 2021, 23, 34-43.	1.2	75
125	Molecular profiling of long-term survivors identifies a subgroup of glioblastoma characterized by chromosome 19/20 co-gain. <i>Acta Neuropathologica</i> , 2015, 130, 419-434.	7.7	74
126	Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. <i>Cell Reports</i> , 2019, 29, 2338-2354.e7.	6.4	74



#	ARTICLE	IF	CITATIONS
127	The RNA-Binding Protein Musashi1 Affects Medulloblastoma Growth via a Network of Cancer-Related Genes and Is an Indicator of Poor Prognosis. <i>American Journal of Pathology</i> , 2012, 181, 1762-1772.	3.8	73
128	Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. <i>Neuro-Oncology</i> , 2013, 15, 1644-1651.	1.2	73
129	Integrated molecular characterization of IDH <sup>mutant</sup> glioblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2019, 45, 108-118.	3.2	68
130	An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 1344-1348.	8.2	68
131	Genome-wide molecular characterization of central nervous system primitive neuroectodermal tumor and pineoblastoma. <i>Neuro-Oncology</i> , 2011, 13, 866-879.	1.2	67
132	Hypermethylation of the Inactive X Chromosome Is a Frequent Event in Cancer. <i>Cell</i> , 2013, 155, 567-581.	28.9	67
133	Methylation profiling of choroid plexus tumors reveals 3 clinically distinct subgroups. <i>Neuro-Oncology</i> , 2016, 18, 790-796.	1.2	67
134	Immunohistochemical markers for intracranial ependymoma recurrence. <i>Journal of the Neurological Sciences</i> , 2000, 177, 72-82.	0.6	66
135	Biological and clinical heterogeneity of MYCN-amplified medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 515-527.	7.7	66
136	Targeting class I histone deacetylase 2 in MYC amplified group 3 medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2015, 3, 22.	5.2	66
137	Defective DNA damage repair leads to frequent catastrophic genomic events in murine and human tumors. <i>Nature Communications</i> , 2018, 9, 4760.	12.8	66
138	YAP1 subgroup supratentorial ependymoma requires TEAD and nuclear factor I-mediated transcriptional programmes for tumorigenesis. <i>Nature Communications</i> , 2019, 10, 3914.	12.8	65
139	Comprehensive Analysis of Chromatin States in Atypical Teratoid/Rhabdoid Tumor Identifies Diverging Roles for SWI/SNF and Polycomb in Gene Regulation. <i>Cancer Cell</i> , 2019, 35, 95-110.e8.	16.8	65
140	Immunohistochemical markers for prognosis of ependymal neoplasms. <i>Journal of Neuro-Oncology</i> , 2002, 58, 255-270.	2.9	64
141	Role of LIM and SH3 Protein 1 (LASP1) in the Metastatic Dissemination of Medulloblastoma. <i>Cancer Research</i> , 2010, 70, 8003-8014.	0.9	62
142	MicroRNA-182 promotes leptomeningeal spread of non-sonic hedgehog-medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 529-538.	7.7	60
143	FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma. <i>EMBO Journal</i> , 2016, 35, 2192-2212.	7.8	58
144	Cribiform neuroepithelial tumor: molecular characterization of a SMARCB1-deficient non-rhabdoid tumor with favorable long-term outcome. <i>Brain Pathology</i> , 2017, 27, 411-418.	4.1	58

#	ARTICLE	IF	CITATIONS
145	Nonmetastatic Medulloblastoma of Early Childhood: Results From the Prospective Clinical Trial HIT-2000 and An Extended Validation Cohort. <i>Journal of Clinical Oncology</i> , 2020, 38, 2028-2040.	1.6	58
146	FGFR1:TACC1 fusion is a frequent event in molecularly defined extraventricular neurocytoma. <i>Acta Neuropathologica</i> , 2018, 136, 293-302.	7.7	56
147	The Senescence-associated Secretory Phenotype Mediates Oncogene-induced Senescence in Pediatric Pilocytic Astrocytoma. <i>Clinical Cancer Research</i> , 2019, 25, 1851-1866.	7.0	55
148	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. <i>Acta Neuropathologica</i> , 2021, 141, 85-100.	7.7	52
149	Foretinib Is Effective Therapy for Metastatic Sonic Hedgehog Medulloblastoma. <i>Cancer Research</i> , 2015, 75, 134-146.	0.9	51
150	Primary intracranial sarcomas with DICER1 mutation often contain prominent eosinophilic cytoplasmic globules and can occur in the setting of neurofibromatosis type 1. <i>Acta Neuropathologica</i> , 2019, 137, 521-525.	7.7	51
151	Diffuse glioneuronal tumour with oligodendroglioma-like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14. <i>Neuropathology and Applied Neurobiology</i> , 2020, 46, 422-430.	3.2	51
152	Clinical utility of fluorescence in situ hybridization (FISH) in nonbrainstem glioblastomas of childhood. <i>Modern Pathology</i> , 2005, 18, 1258-1263.	5.5	50
153	Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. <i>Acta Neuropathologica</i> , 2020, 139, 243-257.	7.7	50
154	Overcoming multiple drug resistance mechanisms in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 57.	5.2	49
155	HGNET-BCOR Tumors of the Cerebellum. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1254-1260.	3.7	49
156	Glioblastoma epigenome profiling identifies SOX10 as a master regulator of molecular tumour subtype. <i>Nature Communications</i> , 2020, 11, 6434.	12.8	48
157	Genetically distinct and clinically relevant subtypes of glioblastoma defined by array-based comparative genomic hybridization (array-CGH). <i>Acta Neuropathologica</i> , 2006, 111, 465-474.	7.7	47
158	Genomic profiling of Acute lymphoblastic leukemia in ataxia telangiectasia patients reveals tight link between ATM mutations and chromothripsis. <i>Leukemia</i> , 2017, 31, 2048-2056.	7.2	47
159	ETMR: a tumor entity in its infancy. <i>Acta Neuropathologica</i> , 2020, 140, 249-266.	7.7	47
160	Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. <i>Neuro-Oncology</i> , 2021, 23, 1360-1370.	1.2	46
161	YAP1-fusions in pediatric NF2-wildtype meningioma. <i>Acta Neuropathologica</i> , 2020, 139, 215-218.	7.7	45
162	Hedgehog-mediated regulation of PPAR $\beta$ controls metabolic patterns in neural precursors and shh-driven medulloblastoma. <i>Acta Neuropathologica</i> , 2012, 123, 587-600.	7.7	43

#	ARTICLE	IF	CITATIONS
163	The Shh Receptor Boc Promotes Progression of Early Medulloblastoma to Advanced Tumors. <i>Developmental Cell</i> , 2014, 31, 34-47.	7.0	43
164	Novel MYC-driven medulloblastoma models from multiple embryonic cerebellar cells. <i>Oncogene</i> , 2017, 36, 5231-5242.	5.9	43
165	Papillary glioneuronal tumor (PGNT) exhibits a characteristic methylation profile and fusions involving PRKCA. <i>Acta Neuropathologica</i> , 2019, 137, 837-846.	7.7	43
166	Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing. <i>Oncotarget</i> , 2017, 8, 11460-11479.	1.8	43
167	Telomere dysfunction and chromothripsis. <i>International Journal of Cancer</i> , 2016, 138, 2905-2914.	5.1	42
168	Routine RNA sequencing of formalin-fixed paraffin-embedded specimens in neuropathology diagnostics identifies diagnostically and therapeutically relevant gene fusions. <i>Acta Neuropathologica</i> , 2019, 138, 827-835.	7.7	42
169	Isochromosome breakpoints on 17p in medulloblastoma are flanked by different classes of DNA sequence repeats. <i>Genes Chromosomes and Cancer</i> , 2006, 45, 401-410.	2.8	41
170	Nestin Expression Identifies Ependymoma Patients with Poor Outcome. <i>Brain Pathology</i> , 2012, 22, 848-860.	4.1	40
171	Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype. <i>Clinical Cancer Research</i> , 2015, 21, 3750-3758.	7.0	40
172	Clinical Outcomes and Patient-Matched Molecular Composition of Relapsed Medulloblastoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 807-821.	1.6	40
173	Papillary Tumor of the Pineal Region: A Distinct Molecular Entity. <i>Brain Pathology</i> , 2016, 26, 199-205.	4.1	39
174	Preclinical drug screen reveals topotecan, actinomycin D, and volasertib as potential new therapeutic candidates for ETMR brain tumor patients. <i>Neuro-Oncology</i> , 2017, 19, 1607-1617.	1.2	39
175	Desmoplastic Infantile Ganglioglioma/Astrocytoma (DIG/DIA) Are Distinct Entities with Frequent BRAFV600 Mutations. <i>Molecular Cancer Research</i> , 2018, 16, 1491-1498.	3.4	39
176	Droplet digital PCR is a powerful technique to demonstrate frequent <i>FGFR1</i> duplication in dysembryoplastic neuroepithelial tumors. <i>Oncotarget</i> , 2017, 8, 2104-2113.	1.8	39
177	Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. <i>Neuropathology</i> , 2015, 35, 538-544.	1.2	38
178	DNA-methylation profiling discloses significant advantages over NanoString method for molecular classification of medulloblastoma. <i>Acta Neuropathologica</i> , 2017, 134, 965-967.	7.7	38
179	A mouse model for embryonal tumors with multilayered rosettes uncovers the therapeutic potential of Sonic-hedgehog inhibitors. <i>Nature Medicine</i> , 2017, 23, 1191-1202.	30.7	38
180	WNT activation by lithium abrogates TP53 mutation associated radiation resistance in medulloblastoma. <i>Acta Neuropathologica Communications</i> , 2014, 2, 174.	5.2	37

#	ARTICLE	IF	CITATIONS
181	Myxoid glioneuronal tumor of the septum pellucidum and lateral ventricle is defined by a recurrent PDGFRA p.K385 mutation and DNT-like methylation profile. <i>Acta Neuropathologica</i> , 2018, 136, 339-343.	7.7	37
182	Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities. <i>Acta Neuropathologica Communications</i> , 2019, 7, 163.	5.2	37
183	Integrated molecular and clinical analysis of low-grade gliomas in children with neurofibromatosis type 1 (NF1). <i>Acta Neuropathologica</i> , 2021, 141, 605-617.	7.7	36
184	PATZ1 fusions define a novel molecularly distinct neuroepithelial tumor entity with a broad histological spectrum. <i>Acta Neuropathologica</i> , 2021, 142, 841-857.	7.7	36
185	Distinct Histomorphology in Molecular Subgroups of Glioblastomas in Young Patients. <i>Journal of Neuropathology and Experimental Neurology</i> , 2016, 75, 408-414.	1.7	35
186	CSF1R inhibition depletes tumor-associated macrophages and attenuates tumor progression in a mouse sonic Hedgehog-Medulloblastoma model. <i>Oncogene</i> , 2021, 40, 396-407.	5.9	35
187	The Transcription Factor Evi-1 Is Overexpressed, Promotes Proliferation, and Is Prognostically Unfavorable in Infratentorial Ependymomas. <i>Clinical Cancer Research</i> , 2011, 17, 3631-3637.	7.0	34
188	Somatic mutations of <i>DICER1</i> and <i>KMT2D</i> are frequent in intraocular medulloepitheliomas. <i>Genes Chromosomes and Cancer</i> , 2016, 55, 418-427.	2.8	34
189	Lateral cerebellum is preferentially sensitive to high sonic hedgehog signaling and medulloblastoma formation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 3392-3397.	7.1	34
190	Subgroup and subtype-specific outcomes in adult medulloblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 859-871.	7.7	34
191	Recurrent fusions in <i>PLAGL1</i> define a distinct subset of pediatric-type supratentorial neuroepithelial tumors. <i>Acta Neuropathologica</i> , 2021, 142, 827-839.	7.7	33
192	Tissue Factor Regulation by miR-520g in Primitive Neuronal Brain Tumor Cells. <i>American Journal of Pathology</i> , 2016, 186, 446-459.	3.8	32
193	Telomerase activation in posterior fossa group A ependymomas is associated with dismal prognosis and chromosome 1q gain. <i>Neuro-Oncology</i> , 2017, 19, 1183-1194.	1.2	31
194	DNA methylation profiling is a method of choice for molecular verification of pediatric WNT-activated medulloblastomas. <i>Neuro-Oncology</i> , 2019, 21, 214-221.	1.2	31
195	Update on molecular and genetic alterations in adult medulloblastoma. <i>Memo - Magazine of European Medical Oncology</i> , 2012, 5, 228-232.	0.5	29
196	Duplications of <i>KIAA1549</i> and <i>BRAF</i> screening by Droplet Digital PCR from formalin-fixed paraffin-embedded DNA is an accurate alternative for <i>KIAA1549</i> - <i>BRAF</i> fusion detection in pilocytic astrocytomas. <i>Modern Pathology</i> , 2018, 31, 1490-1501.	5.5	29
197	Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. <i>Science Translational Medicine</i> , 2021, 13, eabc0497.	12.4	29
198	Intraocular Medulloepitheliomas and Embryonal Tumors With Multilayered Rosettes of the Brain: Comparative Roles of <i>LIN28A</i> and <i>C19MC</i> . <i>American Journal of Ophthalmology</i> , 2015, 159, 1065-1074.e1.	3.3	28

#	ARTICLE	IF	CITATIONS
199	Nestin Mediates Hedgehog Pathway Tumorigenesis. <i>Cancer Research</i> , 2016, 76, 5573-5583.	0.9	28
200	Mosaic trisomy of chromosome 1q in human brain tissue associates with unilateral polymicrogyria, very early-onset focal epilepsy, and severe developmental delay. <i>Acta Neuropathologica</i> , 2020, 140, 881-891.	7.7	28
201	Embryonal tumor with abundant neuropil and true rosettes (ETANTR) with loss of morphological but retained genetic key features during progression. <i>Acta Neuropathologica</i> , 2011, 122, 787-790.	7.7	27
202	Low-dose Actinomycin-D treatment re-establishes the tumoursuppressive function of P53 in RELA-positive ependymoma. <i>Oncotarget</i> , 2016, 7, 61860-61873.	1.8	27
203	Intratumoral platelet aggregate formation in a murine preclinical glioma model depends on podoplanin expression on tumor cells. <i>Blood Advances</i> , 2019, 3, 1092-1102.	5.2	25
204	Stepwise accumulation of distinct genomic aberrations in a patient with progressively metastasizing ependymoma. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 229-238.	2.8	24
205	Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1. <i>Acta Neuropathologica</i> , 2021, 142, 179-189.	7.7	24
206	Radiation-induced gliomas represent H3-IDH-wild type pediatric gliomas with recurrent PDGFRA amplification and loss of CDKN2A/B. <i>Nature Communications</i> , 2021, 12, 5530.	12.8	24
207	Accumulation of genomic aberrations during clinical progression of medulloblastoma. <i>Acta Neuropathologica</i> , 2008, 116, 383-390.	7.7	23
208	Molecular analysis of pediatric CNS-PNET revealed nosologic heterogeneity and potent diagnostic markers for CNS neuroblastoma with FOXR2-activation. <i>Acta Neuropathologica Communications</i> , 2021, 9, 20.	5.2	23
209	Molecular approaches to ependymoma. <i>Current Opinion in Neurology</i> , 2012, 25, 745-750.	3.6	22
210	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	1.2	22
211	Emerging Insights into the Ependymoma Epigenome. <i>Brain Pathology</i> , 2013, 23, 206-209.	4.1	21
212	Molecular characterization of medulloblastomas with extensive nodularity (MBEN). <i>Acta Neuropathologica</i> , 2018, 136, 303-313.	7.7	20
213	An essential role for p38 MAPK in cerebellar granule neuron precursor proliferation. <i>Acta Neuropathologica</i> , 2012, 123, 573-586.	7.7	19
214	Long-term survival in a case of ETANTR with histological features of neuronal maturation after therapy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 603-607.	2.8	19
215	Differential nuclear $\alpha$ TRX expression in sarcomas. <i>Histopathology</i> , 2016, 68, 738-745.	2.9	19
216	Oligosarcomas, IDH-mutant are distinct and aggressive. <i>Acta Neuropathologica</i> , 2022, 143, 263-281.	7.7	18

#	ARTICLE	IF	CITATIONS
217	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. <i>Acta Neuropathologica</i> , 2018, 135, 635-638.	7.7	17
218	Functional loss of a noncanonical BCOR-PRC1.1 complex accelerates SHH-driven medulloblastoma formation. <i>Genes and Development</i> , 2020, 34, 1161-1176.	5.9	16
219	GOPC:ROS1 and other ROS1 fusions represent a rare but recurrent drug target in a variety of glioma types. <i>Acta Neuropathologica</i> , 2021, 142, 1065-1069.	7.7	16
220	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. <i>Methods</i> , 2017, 114, 60-73.	3.8	15
221	Integrating Tenascin-C protein expression and 1q25 copy number status in pediatric intracranial ependymoma prognostication: A new model for risk stratification. <i>PLoS ONE</i> , 2017, 12, e0178351.	2.5	15
222	Pediatric Targeted Therapy: Clinical Feasibility of Personalized Diagnostics in Children with Relapsed and Progressive Tumors. <i>Brain Pathology</i> , 2016, 26, 506-516.	4.1	14
223	Non-random aneuploidy specifies subgroups of pilocytic astrocytoma and correlates with older age. <i>Oncotarget</i> , 2015, 6, 31844-31856.	1.8	14
224	Novel oncogene amplifications in tumors from a family with Li-Fraumeni syndrome. <i>Genes Chromosomes and Cancer</i> , 2009, 48, 558-568.	2.8	13
225	DNA copy number alterations in central primitive neuroectodermal tumors and tumors of the pineal region: an international individual patient data meta-analysis. <i>Journal of Neuro-Oncology</i> , 2012, 109, 415-423.	2.9	13
226	Transcriptional profiling of medulloblastoma with extensive nodularity (MBEN) reveals two clinically relevant tumor subsets with VSNL1 as potent prognostic marker. <i>Acta Neuropathologica</i> , 2020, 139, 583-596.	7.7	13
227	A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human Tumors. <i>Cancers</i> , 2021, 13, 230.	3.7	13
228	Somatostatin receptor subtype 2 (sst2) is a potential prognostic marker and a therapeutic target in medulloblastoma. <i>Child's Nervous System</i> , 2013, 29, 1253-1262.	1.1	12
229	Gain of 12p encompassing CCND2 is associated with gemistocytic histology in IDH mutant astrocytomas. <i>Acta Neuropathologica</i> , 2017, 133, 325-327.	7.7	12
230	Accurate calling of KIAA1549-BRAF fusions from DNA of human brain tumours using methylation array-based copy number and gene panel sequencing data. <i>Neuropathology and Applied Neurobiology</i> , 2021, 47, 406-414.	3.2	12
231	Molecular profiling of pediatric meningiomas shows tumor characteristics distinct from adult meningiomas. <i>Acta Neuropathologica</i> , 2021, 142, 873-886.	7.7	12
232	Pleomorphic xanthoastrocytoma is a heterogeneous entity with pTERT mutations prognosticating shorter survival. <i>Acta Neuropathologica Communications</i> , 2022, 10, 5.	5.2	12
233	Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 2010, 32, 511-514.	0.6	11
234	Genetic confirmation that ependymoma can arise as part of multiple endocrine neoplasia type 1 (MEN1) syndrome. <i>Acta Neuropathologica</i> , 2017, 133, 661-663.	7.7	11

#	ARTICLE	IF	CITATIONS
235	Pilocytic astrocytoma demethylation and transcriptional landscapes link bZIP transcription factors to immune response. <i>Neuro-Oncology</i> , 2020, 22, 1327-1338.	1.2	10
236	Desmoplastic/nodular medulloblastomas (DNMB) and medulloblastomas with extensive nodularity (MBEN) disclose similar epigenetic signatures but different transcriptional profiles. <i>Acta Neuropathologica</i> , 2019, 137, 1003-1015.	7.7	9
237	Posterior fossa pilocytic astrocytomas with oligodendroglial features show frequent FGFR1 activation via fusion or mutation. <i>Acta Neuropathologica</i> , 2020, 139, 403-406.	7.7	9
238	Absence of chromosome 19q13.41 amplification in a case of atypical teratoid/rhabdoid tumor with ependymoblastic differentiation. <i>Acta Neuropathologica</i> , 2011, 121, 283-285.	7.7	8
239	Spinal metastasis of gliosarcoma: Array-based comparative genomic hybridization for confirmation of metastatic spread. <i>Journal of Clinical Neuroscience</i> , 2014, 21, 1945-1950.	1.5	8
240	Clinically Tractable Outcome Prediction of Non-WNT/Non-SHH Medulloblastoma Based on TPD52 IHC in a Multicohort Study. <i>Clinical Cancer Research</i> , 2022, 28, 116-128.	7.0	8
241	Integrated molecular analysis of adult sonic hedgehog (SHH)-activated medulloblastomas reveals two clinically relevant tumor subsets with VEGFA as potent prognostic indicator. <i>Neuro-Oncology</i> , 2021, 23, 1576-1585.	1.2	7
242	Carbon ion radiotherapy eradicates medulloblastomas with chromothripsis in an orthotopic Li-Fraumeni patient-derived mouse model. <i>Neuro-Oncology</i> , 2021, 23, 2028-2041.	1.2	7
243	The age of adult pilocytic astrocytoma cells. <i>Oncogene</i> , 2021, 40, 2830-2841.	5.9	6
244	Abstract 4347: Medulloblastoma comprises four distinct diseases. , 2010, , .		6
245	Identification of CD24 as a marker of Patched1 deleted medulloblastoma-initiating neural progenitor cells. <i>PLoS ONE</i> , 2019, 14, e0210665.	2.5	5
246	An optimized workflow to improve reliability of detection of KIAA1549:BRAF fusions from RNA sequencing data. <i>Acta Neuropathologica</i> , 2020, 140, 237-239.	7.7	5
247	Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression. <i>Acta Neuropathologica</i> , 2022, 144, 339-352.	7.7	5
248	<scp>P</scp>aired box gene 8 (<scp>PAX8</scp>) expression is associated with sonic hedgehog (<scp>SHH</scp>)/wingless int (<scp>WNT</scp>) subtypes, desmoplastic histology and patient survival in human medulloblastomas. <i>Neuropathology and Applied Neurobiology</i> , 2015, 41, 165-179.	3.2	4
249	Medulloepithelioma with peculiar clinical presentation, stem cell phenotype and aberrant DNA-methylation profile. <i>CNS Oncology</i> , 2015, 4, 203-212.	3.0	3
250	Reply to J.C. Lindsey et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e348-e349.	1.6	2
251	Molecular progression of SHH-activated medulloblastomas. <i>Acta Neuropathologica</i> , 2019, 138, 327-330.	7.7	2
252	Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab002.	0.7	2

#	ARTICLE	IF	CITATIONS
253	ABCB1 inhibition provides a novel therapeutic target to block TWIST1-induced migration in medulloblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab030.	0.7	2
254	ICGC PedBrain - dissecting the genomic complexity underlying medulloblastoma using whole-genome sequencing. <i>BMC Proceedings</i> , 2012, 6, .	1.6	1
255	Predictive modeling of resistance to SMO-inhibition in a patient-derived orthotopic xenograft model of SHH medulloblastoma. <i>Neuro-Oncology Advances</i> , 2022, 4, vdac026.	0.7	1
256	Ependymoma. <i>Molecular Pathology Library</i> , 2015, , 67-75.	0.1	0
257	GENE-13. PEDIATRIC MENINGIOMAS ARE CHARACTERIZED BY DISTINCT METHYLATION PROFILES DIFFERENT FROM ADULT MENINGIOMAS. <i>Neuro-Oncology</i> , 2019, 21, ii83-ii84.	1.2	0
258	Progressively Metastasizing Ependymoma: Genomic Aberrations. , 2012, , 297-306.		0
259	Co-activation of Sonic hedgehog and Wnt signaling in murine retinal precursor cells drives ocular lesions with features of intraocular medulloepithelioma. <i>Oncogenesis</i> , 2021, 10, 78.	4.9	0